Niclosamide-loaded nanoparticles disrupt Candida biofilms and protect mice from mucosal candidiasis
Open Access
- 17 August 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 20 (8) , e3001762
Abstract
Candida albicans biofilms are a complex multilayer community of cells that are resistant to almost all classes of antifungal drugs. The bottommost layers of biofilms experience nutrient limitation where C. albicans cells are required to respire. We previously reported that a protein Ndu1 is essential for Candida mitochondrial respiration; loss of NDU1 causes inability of C. albicans to grow on alternative carbon sources and triggers early biofilm detachment. Here, we screened a repurposed library of FDA-approved small molecule inhibitors to identify those that prevent NDU1-associated functions. We identified an antihelminthic drug, Niclosamide (NCL), which not only prevented growth on acetate, C. albicans hyphenation and early biofilm growth, but also completely disengaged fully grown biofilms of drug-resistant C. albicans and Candida auris from their growth surface. To overcome the suboptimal solubility and permeability of NCL that is well known to affect its in vivo efficacy, we developed NCL-encapsulated Eudragit EPO (an FDA-approved polymer) nanoparticles (NCL-EPO-NPs) with high niclosamide loading, which also provided long-term stability. The developed NCL-EPO-NPs completely penetrated mature biofilms and attained anti-biofilm activity at low microgram concentrations. NCL-EPO-NPs induced ROS activity in C. albicans and drastically reduced oxygen consumption rate in the fungus, similar to that seen in an NDU1 mutant. NCL-EPO-NPs also significantly abrogated mucocutaneous candidiasis by fluconazole-resistant strains of C. albicans, in mice models of oropharyngeal and vulvovaginal candidiasis. To our knowledge, this is the first study that targets biofilm detachment as a target to get rid of drug-resistant Candida biofilms and uses NPs of an FDA-approved nontoxic drug to improve biofilm penetrability and microbial killing.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI141794)
- National Eye Institute (R24EY033598)
This publication has 84 references indexed in Scilit:
- Mouse model of oropharyngeal candidiasisNature Protocols, 2012
- Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity RegulationEukaryotic Cell, 2011
- Effects of Fluconazole, Amphotericin B, and Caspofungin on Candida albicans Biofilms under Conditions of Flow and on Biofilm DispersionAntimicrobial Agents and Chemotherapy, 2011
- Glucose Promotes Stress Resistance in the Fungal PathogenCandida albicansMolecular Biology of the Cell, 2009
- Biofilm Matrix Regulation by Candida albicans Zap1PLOS Biology, 2009
- Bacterial Endosymbiosis Is Widely Present among Zygomycetes but Does Not Contribute to the Pathogenesis of MucormycosisThe Journal of Infectious Diseases, 2008
- A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testingNature Protocols, 2008
- Role for Cell Density in Antifungal Drug Resistance in Candida albicans BiofilmsAntimicrobial Agents and Chemotherapy, 2007
- Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United StatesClinical Infectious Diseases, 2003
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002